Protagonist Therapeutics (PTGX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
17 Jun, 2026Opening remarks and agenda
The meeting was called to order by Matthew Gosling, EVP and Chief Legal and Business Officer, who introduced the board, executive officers, and external representatives in attendance.
The meeting was held virtually, allowing stockholders to submit questions and vote online.
The agenda included four proposals: election of directors, advisory vote on executive compensation, ratification of the auditor, and approval of the equity incentive plan.
Board and executive committee updates
Board members present included Dr. Dinesh Patel (President & CEO), Harold Selick, Bryan Giraudo, Sarah O'Dowd, William Waddill, and Lewis Williams.
Executive officers present were Dr. Patel, Asif Ali, and Arturo Molina.
Shareholder proposals
Four proposals were presented: election of two Class I directors, advisory approval of executive compensation, ratification of Ernst & Young as auditor, and adoption of the 2026 equity incentive plan.
Latest events from Protagonist Therapeutics
- Strong partnered revenues and a diversified pipeline position the company for major value creation.PTGX
Corporate presentation - Q2 2026 net income hit $162.8M, fueled by ICOTYDE sales and milestone payments; cash at $849.5M.PTGX
Q2 2026 - Two first-in-class therapies near launch, backed by strong partnerships and financial strength.PTGX
TD Cowen 46th Annual Health Care Conference - Icotyde's strong launch and a robust pipeline drive growth, with Rusfertide approval expected soon.PTGX
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Major partnerships, strong pipeline, and financial strength drive growth and shareholder returns.PTGX
Jefferies Global Healthcare Conference 2026 - FDA approved the first oral IL-23R antagonist for moderate-to-severe plaque psoriasis.PTGX
FDA announcement - Rusfertide achieved rapid, sustained Hct control and symptom relief in PV; phase 3 results due 2025.PTGX
Study Update - PN-477, a potent triple agonist, advances toward Phase 1 trials with dual oral and injectable options.PTGX
Status Update - Rusfertide met all efficacy and safety endpoints in phase 3 PV trial; NDA filings planned for 2025.PTGX
Investor Update